| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 65 | 19.1x | 17.8x | Around median | |
Growth | 86 | 19.7% | 7.1% | Top tier | |
Quality | 84 | 11.1% | 4.5% | Top tier | |
Safety | 94 | — | 2.6x | Top tier | |
Capital Return | 61 | — | 2.12% | Around median | |
Momentum | 40 | 32.6% | 2.9% | Bottom tier | |
Sentiment | 85 | 14 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Globus Medical develops therapeutic technologies for the musculoskeletal sector and derives its revenue primarily from spine and trauma products, enabling technologies for surgery and neuromonitoring, as well as the pain neurostimulation business that entered the group through Nevro. The company combines implants and surgical instruments with the Excelsius ecosystem of navigation, robotics, and software, relying on an expanded direct sales force and product launches to increase the use of implants, services, and consumables. The merger with NuVasive and the broader product portfolio have strengthened the business base, while the acquisition of Nevro added the pain treatment market to the platform.
In quarter 2 of fiscal year 2026, revenue reached $789.6 million, an increase of 5.9% on a reported basis and 5.6% in constant currency, while the core business excluding Nevro grew 8.9%. The financial statements recorded gross profit of $548.2 million, net income of $151.6 million, and GAAP diluted earnings per share of $1.10. The GAAP gross margin was 66.8%, while the adjusted gross margin reached 69.4%, and the adjusted earnings before interest, taxes, depreciation, and amortization margin increased to 35.4% from 28% in the comparable period.
Musculoskeletal sales amounted to $763.5 million, or approximately 96.7% of revenue in quarter 2 of fiscal year 2026, and grew 7.5% despite the decline in Nevro, while enabling technologies sales totaled $26.1 million and declined 25.8%. The U.S. market generated revenue of $619.1 million, up 3%, compared with $170.5 million internationally, up 18% on a reported basis and 16.2% in constant currency. On a trailing-twelve-month basis in 2026, EDGAR data show revenue of approximately $3.1 billion and net income of $535.4 million, compared with revenue of $2.9 billion and net income of $537.9 million in fiscal year 2025.
The analyst consensus on GMED is “Buy,” with an average target of $98.88, a low of $80, and a high of $117; the average is approximately 2.5% below the 52-week range peak of $101.4. The $37 spread between targets indicates a notable difference of opinion regarding the impact of margin improvement versus the risks from Nevro and enabling technologies, while the available data do not provide a published earnings multiple for an additional earnings-based comparison.
Figures in the text are as of 2026-08-29; the live price is shown at the top of the page.
Revenue reached $789.6 million, representing reported growth of 5.9%, while the core business excluding Nevro grew 8.9%. U.S. spine grew 7.3%, international spine grew 13.8%, and the trauma business jumped 31%. Conversely, a 14.3% decline in Nevro and a 25.8% decrease in enabling technologies limited the group's growth.
The company recorded GAAP net income of $151.6 million and diluted earnings per share of $1.10. Adjusted net income reached $184.3 million, while adjusted diluted earnings per share increased 55.8% to $1.34. The adjusted gross margin also reached 69.4%, and the adjusted earnings before interest, taxes, depreciation, and amortization margin reached 35.4%.
The acquisition of Nevro expanded the Globus Medical platform into neurostimulation and pain treatment, but it remained a drag on revenue in quarter 2 of fiscal year 2026, with an annual decline of 14.3%. The company refilled approximately 75% of open positions during the quarter and aims to restore historical trial volumes in late quarter 4 of fiscal year 2026. At the same time, Nevro's adjusted earnings before interest, taxes, depreciation, and amortization margin improved from negative 1.4% in the comparable period to 22.4%.
Automated analysis for informational purposes only — not investment advice.
The company launched the AUTOBAHN Hip fastener, TENSOR Suture button system, and RELINE ONE in quarter 2 of fiscal year 2026. It also scheduled the launch of patient-specific SCRIPT spacers and rods for quarter 3 of fiscal year 2026 after receiving FDA 510(k) clearances. Management expects SCRIPT cases to be manufactured within one week to ten days, with integration into ExcelsiusGPS, ExcelsiusHub, and ExcelsiusXR.
The company maintained revenue guidance at $3.18–$3.22 billion, representing growth of between 8.2% and 9.6% over fiscal year 2025. It raised adjusted diluted earnings per share guidance to $4.95–$5.05 from the previous range of $4.70–$4.80. It also expects an adjusted gross margin of between 69% and 70% and research and development spending equal to 5%–6% of net sales.
Cash, cash equivalents, and marketable securities totaled $840.5 million as of June 30, 2026, following operating cash flow of $412.1 million in the first half of fiscal year 2026. The company spent $136.1 million to repurchase 1.6 million shares in quarter 2, with $253.9 million remaining under the authorization. Management prioritizes internal investment in product development, followed by spending on instrument sets, facilities, and equipment, while continuing share repurchases and evaluating complementary acquisitions.
